Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Bevacizumab + Chemo in NSCLC
NCT02316327Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2013
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Early tumour response in terms of blood flow compared to Objective Response Rate at Day 42. Started Jul 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02316327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316327.